Pfizer is looking to newer products and acquisitions to offset a declining Covid business.

Pharma giant is working hard to offset its post-Covid hangover but faces a patent cliff on many top-selling medicines ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth ...

Operational revenue from Pfizer’s Covid vaccine Comirnaty and Paxlovid pill to treat the illness declined 59% and 63%, ...

The company said it would exit operations at some manufacturing plants in Germany and Singapore, and that as many as 1,860 ...

The German company that pioneered one of the first mRNA coronavirus vaccines is halting production, handing the reins to ...

Pfizer is also demonstrating that its commercial portfolio can flourish beyond the historically mammoth sales of its COVID-19 ...

In the latest update to COVID and vaccine-related discourse bubbling up at the FDA, agency officials have recently blocked ...

Pfizer has today posted better than expected quarterly earnings and said a recent favourable European court ruling on its ...

FDA officials stopped publication of studies backing COVID-19 and shingles vaccine safety, citing data concerns.